Evidence map›Paper›PMID 39350015›Full record

ArticleBMC genomics2024

Fine mapping of RNA isoform diversity using an innovative targeted long-read RNA sequencing protocol with novel dedicated bioinformatics pipeline.

Camille Aucouturier, Nicolas Soirat, Laurent Castéra, Denis Bertrand, Alexandre Atkinson, Thibaut Lavolé, Nicolas Goardon, Céline Quesnelle, Julien Levilly, Sosthène Barbachou and 10 more

Abstract read
In one paragraph

Article in BMC genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Camille AucouturierLaboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Nicolas SoiratLaboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Laurent CastéraLaboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Denis BertrandSeqOne Genomics, Montpellier, 34000, France.
Alexandre AtkinsonLaboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Thibaut LavoléLaboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Nicolas GoardonLaboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Céline QuesnelleLaboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Julien LevillyLaboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Sosthène BarbachouLaboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Angelina LegrosLaboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Olivier CaronDépartement Médecine Oncologique, Institut Gustave Roussy, Villejuif, France.
Louise CrivelliService d'Oncogénétique, Centre Eugène Marquis, Rennes, France.
Philippe DenizeauService de génétique clinique, Centre Hospitalier Universitaire Rennes, Rennes, France.
Pascaline BerthetService d'Oncogénétique, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Agathe RicouLaboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Flavie BoulouardLaboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Dominique VaurLaboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Sophie Krieger *Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.
Raphael Leman *Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France. r.leman@baclesse.unicancer.fr.

Funding

French Cancéropôle Nord-Ouest (CNO) 2018/06
6 · The paper itself

Abstract

backgroundSolving the structure of mRNA transcripts is a major challenge for both research and molecular diagnostic purposes. Current approaches based on short-read RNA sequencing and RT-PCR techniques cannot fully explore the complexity of transcript structure. The emergence of third-generation long-read sequencing addresses this problem by solving this sequence directly. However, genes with low expression levels are difficult to study with the whole transcriptome sequencing approach. To fix this technical limitation, we propose a novel method to capture transcripts of a gene panel using a targeted enrichment approach suitable for Pacific Biosciences and Oxford Nanopore Technologies platforms.

resultsWe designed a set of probes to capture transcripts of a panel of genes involved in hereditary breast and ovarian cancer syndrome. We present SOSTAR (iSofOrmS annoTAtoR), a versatile pipeline to assemble, quantify and annotate isoforms from long read sequencing using a new tool specially designed for this application. The significant enrichment of transcripts by our capture protocol, together with the SOSTAR annotation, allowed the identification of 1,231 unique transcripts within the gene panel from the eight patients sequenced. The structure of these transcripts was annotated with a resolution of one base relative to a reference transcript. All major alternative splicing events of the BRCA1 and BRCA2 genes described in the literature were found. Complex splicing events such as pseudoexons were correctly annotated. SOSTAR enabled the identification of abnormal transcripts in the positive controls. In addition, a case of unexplained inheritance in a family with a history of breast and ovarian cancer was solved by identifying an SVA retrotransposon in intron 13 of the BRCA1 gene.

conclusionsWe have validated a new protocol for the enrichment of transcripts of interest using probes adapted to the ONT and PacBio platforms. This protocol allows a complete description of the alternative structures of transcripts, the estimation of their expression and the identification of aberrant transcripts in a single experiment. This proof-of-concept opens new possibilities for RNA structure exploration in both research and molecular diagnostics.

Indexed as

Computational BiologyRNA IsoformsSequence Analysis, RNAAlternative SplicingBRCA1 ProteinBRCA2 ProteinFemaleHereditary Breast and Ovarian Cancer SyndromeHigh-Throughput Nucleotide SequencingHumansBRCA1 ProteinBRCA2 ProteinRNA IsoformsAutomatic annotationHBOCIsoform assemblyLong read sequencingRNA splicing

Identifiers

PMID39350015
PMCPMC11440762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.